Jazz Pharmaceuticals(JAZZ) ZACKS·2025-02-05 18:11Core Viewpoint - Jazz Pharmaceuticals (JAZZ) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Earnings Performance - The company has a solid track record of surpassing earnings estimates, with an average surprise of 17.04% over the last two quarters [2]. - In the last reported quarter, Jazz achieved earnings of 5.47 per share by 20.84%. In the previous quarter, it reported earnings of 4.68 per share, resulting in a surprise of 13.25% [3]. Earnings Estimates and Predictions - Estimates for Jazz have been trending upward, influenced by its history of earnings surprises. The stock currently has a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of another earnings beat [4]. - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise, suggesting that out of 10 such stocks, approximately seven may exceed consensus estimates [5]. Earnings ESP and Analyst Sentiment - Jazz has an Earnings ESP of +1.27%, indicating that analysts are optimistic about its near-term earnings potential. This positive ESP, combined with a Zacks Rank of 3, suggests a possible upcoming earnings beat [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate than earlier predictions [6].